Insight Molecular Diagnostics (IMDX) Change in Accured Expenses (2015 - 2026)

Insight Molecular Diagnostics has disclosed Change in Accured Expenses across 12 years of filings, most recently posting -$105000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$105000.0, down 110.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (up 32.81% YoY), and the FY2025 annual result was $2.6 million, up 173.63% from the prior year.
• Change in Accured Expenses came in at -$105000.0 for Q1 2026 at Insight Molecular Diagnostics, down from $3.6 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.6 million in Q4 2025 to a low of -$3.1 million in Q2 2025.
• The 5-year median for Change in Accured Expenses is $126000.0 (2023), against an average of -$56000.0.
• Across the five-year window, Change in Accured Expenses slumped 12576.19% in 2023 and soared 415.08% in 2024, its largest moves.
• Insight Molecular Diagnostics' Change in Accured Expenses stood at -$125000.0 in 2022, then sank by 351.2% to -$564000.0 in 2023, then soared by 224.82% to $704000.0 in 2024, then surged by 404.97% to $3.6 million in 2025, then plunged by 102.95% to -$105000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$105000.0 (Q1 2026), $3.6 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.